Vera Therapeutics: T. Rowe Price reports 3.8% stake
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Vera Therapeutics, Inc. (VERA) common stock was the subject of a Schedule 13G amendment by T. Rowe Price Associates, Inc., which reported an aggregate beneficial ownership amount of 2,753,148 shares, or 3.8% of the class. T. Rowe Price Associates expressly denied being the beneficial owner of the securities.
Key Figures
Key Terms
beneficial ownership regulatory
sole voting power regulatory
sole dispositive power regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.